Gautam Borthakur - Concepedia

Author

Gautam Borthakur

The University of Texas MD Anderson Cancer Center

Also Known As

G. Borthakur, GAUTAM BORTHAKUR, Gautam Borthakur, Ghayas C. Issa

178

Publications

1.3K

Citations

H-Index

Concepts

All Affiliations

The University of Texas MD Anderson Cancer Center The University of Texas Health Science Center at Houston Dana-Farber Cancer Institute Sylvester Comprehensive Cancer Center University of Miami

About

Gautam Borthakur is an author at The University of Texas MD Anderson Cancer Center specializing in medicine, oncology, and cancer research.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	6	6	185
2	Health Sciences	3	3	78
3	Immunology	3	3	78
4	Pathology	2	2	40
5	Biostatistics	1	1	34

Gautam Borthakur

Publications

858

Citations

H-Index

Page 1

	Year	Citations
The Combination of Quizartinib with Azacitidine or Low Dose Cytarabine Is Highly Active in Patients (Pts) with FLT3-ITD Mutated Myeloid Leukemias: Interim Report of a Phase I/II Trial Mahesh Swaminathan, Hagop M. Kantarjian, Naval Daver, Blood	2017	73
A phase 2 study of nivolumab combined with ibrutinib in patients with diffuse large B-cell Richter transformation of CLL Nitin Jain, Jayastu Senapati, Beenu Thakral, Blood Advances	2022	72
Ruxolitinib in combination with Lenalidomide as therapy for patients with myelofibrosis Naval Daver, Jörge E. Cortes, Kate J. Newberry, Haematologica	2015	62
Phase I/II Study of Azacitidine (AZA) with Venetoclax (VEN) and Magrolimab (Magro) in Patients (pts) with Newly Diagnosed (ND) Older/Unfit or High-Risk Acute Myeloid Leukemia (AML) and Relapsed/Refractory (R/R) AML Naval Daver, Jayastu Senapati, Abhishek Maiti, Blood Hematological MalignancyOncologyPhase I/ii StudyMixed-phenotype Acute LeukemiaPharmacotherapy	2022	62
Targeted therapy with the mutant <i>IDH2</i> inhibitor enasidenib for high-risk <i>IDH2</i>-mutant myelodysplastic syndrome Courtney D. DiNardo, Sangeetha Venugopal, Curtis A. Lachowiez, Blood Advances	2022	60
A phase I study of danusertib (PHA-739358) in adult patients with accelerated or blastic phase chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia resistant or intolerant to imatinib and/or other second generation c-ABL therapy Gautam Borthakur, Hervé Dombret, Philippe Schafhausen, Haematologica	2015	57
A phase 1/2 study of azacitidine, venetoclax and pevonedistat in newly diagnosed secondary AML and in MDS or CMML after failure of hypomethylating agents Nicholas J. Short, Muharrem Müftüoğlu, Faustine Ong, Journal of Hematology & Oncology	2023	48
Updated Results from a Phase I/II Study of the Triplet Combination of Azacitidine, Venetoclax and Gilteritinib for Patients with <i>FLT3</i>-Mutated Acute Myeloid Leukemia Nicholas J. Short, Courtney D. DiNardo, Naval Daver, Blood Hematological MalignancyPhase I/ii StudyMedicineAcute Myeloid LeukemiaImmunology	2022	38
Assessment at 6 months may be warranted for patients with chronic myeloid leukemia with no major cytogenetic response at 3 months Aziz Nazha, Hagop M. Kantarjian, Preetesh Jain, Haematologica Hematological MalignancyChronic Myeloid LeukemiaMajor Cytogenetic ResponseMedicineMixed-phenotype Acute Leukemia	2013	34
Undetectable measurable residual disease is associated with improved outcomes in AML irrespective of treatment intensity Alexandre Bazinet, Tapan M. Kadia, Nicholas J. Short, Blood Advances	2023	26

Page 1